Long-term administration of amnion-derived cellular cytokine suspension promotes functional recovery in a model of penetrating ballistic-like brain injury.

BACKGROUND: Previous work has shown that human amnion-derived progenitor (AMP) cell therapy is neuroprotective in a penetrating ballistic-like brain injury (PBBI) model. However, the neuroprotective capacity of AMP cells seemed to be mediated by the sustained secretion of AMP cell-derived neurotrophic factors, which are abundant in the amnion-derived cellular cytokine suspension (ACCS). To test this theory, the current study assessed the neuroprotective efficacy of long-term ACCS delivery in the PBBI model. METHODS: Experiment 1 assessed the bioactive stability and neuroprotective capacity of ACCS in an in vitro model of neurodegeneration. Experiment 2 evaluated the therapeutic effects of ACCS delivery initiated 15 minutes after PBBI and continued for 2 weeks after injury. Experiment 3 was designed to identify the therapeutic window for long-term ACCS delivery in the PBBI model. Outcome metrics included neurobehavioral assessments and neuropathologic measures of neuroinflammation and axonal/neuronal degeneration. RESULTS: Experiment 1 demonstrated that ACCS is thermally stable for 1 week at 37°C and that ACCS treatment protected neurite against staurosporine toxicity. Experiment 2 identified the optimal infusion rate of ACCS (1 µL/h) and demonstrated that long-term infusion of ACCS was capable of promoting significant protection against PBBI-induced neuropathology and motor abnormalities, but was not sufficient for reducing cognitive deficits. Finally, the results of Experiment 3 showed that ACCS is effective in promoting significant neuroprotection even when onset of treatment is delayed out to 24 hours (but not 48 hours) after PBBI. CONCLUSIONS: Collectively, our results support the hypothesis that the neuroprotective effects of AMP cells are mediated through a sustained delivery of ACCS, which implicates ACCS as a promising neuroprotection agent for clinical study.

Amnion-derived cellular cytokine solution: a physiological combination of cytokines for wound healing.

OBJECTIVE: Wound repair is a complex integration of dynamic processes mediated by humeral messages controlling the levels of cytokines, growth factors, and matrix metalloproteinases in the wound space. Isolated growth factors and growth factor combinations have been used to accelerate wound healing with limited success. A cellular cytokine solution can be collected by harvesting the proteins released from amnion-derived multipotent progenitor cells. The purpose of this study was to compare levels of cytokines/growth factors in amnion-derived cellular cytokine solution with physiological levels reported in the medical literature. METHODS: Amnion-derived multipotent progenitor cells were grown to confluency, and the proteins secreted were characterized by qualitative and quantitative analysis. These results were compared with physiologic levels reported in the medical literature. RESULTS: The results demonstrated that amnion-derived cellular cytokine solution contained physiologic levels of cytokines relevant to wound healing, including platelet-derived growth factor, vascular endothelial growth factor, angiogenin, transforming growth factor beta 2, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2. The ranges (mean +/- standard deviation) were as follows: platelet-derived growth factor, 86 +/- 33 pg/mL; vascular endothelial growth factor, 5.7 +/- 1.5 ng/mL; angiogenin, 1.0 +/- 0.33 ng/mL; transforming growth factor beta 2, 500 +/- 330pg/mL; tissue inhibitor of metalloproteinase-1, 530 +/- 140 ng/mL; and tissue inhibitor of metalloproteinase-2230 +/- 40 ng/mL. These levels are comparable with the physiologic levels reported in the literature. CONCLUSIONS: The physiologic levels of cytokines important to healing found in amnion-derived cellular cytokine solution suggest that amnion-derived cellular cytokine solution may be of benefit in healing certain acute and chronic wounds.

Dean vortex membrane microfiltration and diafiltration of rBDNF E. coli inclusion bodies.

Cross-flow microfiltration (CMF) and diafiltration were used to concentrate and purify recombinant Brain-Derived Neutrophic Factor (rBDNF) inclusion bodies from an E. coli cell suspension and a homogenized E. coli cell suspension (homogenate/lysate). Although these processes have been tested industrially in pilot scale with conventional linear membrane microfiltration modules, their performances were severely limited due to membrane fouling. The purpose of this work was to determine whether Dean vortex microfiltration with controlled centrifugal instabilities (Dean vortices produced in helical flow) could be used to improve filtration performance over that observed with conventional linear cross-flow microfiltration (CMF). For the microfiltration experiments with the feeds containing cell and homogenate suspensions, improvements in flux of about 50 and 70%, respectively, were obtained with the helical module as compared with that obtained with the linear module. For diafiltration with the homogenate suspension as feed, solute transport (as measured by mass) was from 100 to 40% higher after 40 and 100 min, respectively, with the helical module as compared with that obtained with the linear module. In the presence of the neutral surfactant, Tween 20, solute transport for diafiltration was at least 25 times higher during the first 10 min of operation and 100% higher after 300 min with the helical module as compared with that obtained with the linear module. Clearly, improved filtration performance, a purer and more concentrated product, and substantial savings can be expected with the new Dean vortex filters.